Myeloproliferative Neoplasms Epidemiology Forecast 2026-2035

Myeloproliferative neoplasms (MPNs) are rare clonal hematologic malignancies characterized by excessive production of one or more myeloid lineage cells. According to Xinyue Gou et al., 2025, global MDS/MPN incidence increased from 171,132 cases in 1990 to 341,017 cases in 2021, as per estimates from the Global Burden of Disease 2021 database, with a higher burden observed in men. According to myeloproliferative neoplasms epidemiology forecast, prevalence is projected to rise further due to population aging, enhanced diagnostic capabilities, and improved disease awareness worldwide.

Myeloproliferative Neoplasms Epidemiology Forecast Report Coverage

The analyst's “Myeloproliferative Neoplasms Epidemiology Forecast Report 2026-2035” offers comprehensive information on the prevalence and demographics of myeloproliferative neoplasms. It projects the future incidence and prevalence rates of myeloproliferative neoplasms cases across various populations. The study covers age, gender, and type as major determinants of the myeloproliferative neoplasms population. The report highlights patterns in the prevalence of myeloproliferative neoplasms over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on the epidemiology of myeloproliferative neoplasms in the 8 major markets.

Regions Covered

• The United States
• Germany
• France
• Italy
• Spain
• The United Kingdom
• Japan
• India

Myeloproliferative Neoplasms Understanding: Disease Overview

Myeloproliferative neoplasms (MPNs) are clonal hematopoietic stem cell disorders characterized by the abnormal and excessive production of mature blood cells in the bone marrow due to acquired genetic mutations affecting cell signaling pathways. These conditions result in dysregulated proliferation of erythroid, myeloid, or megakaryocytic lineages, leading to increased blood viscosity, thrombosis risk, and progressive marrow dysfunction. MPNs are commonly classified into four classical subtypes: chronic myeloid leukemia (CML), polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). Disease progression varies among subtypes, with some cases progressing to bone marrow failure or acute leukemia over time.

Myeloproliferative Neoplasms Epidemiology Perspective

The myeloproliferative neoplasms epidemiology division offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. The analyst provides both current and predicted trends for myeloproliferative neoplasms epidemiology scenario by examining a wide range of studies. Additionally, the report covers the diagnosed patient population for myeloproliferative neoplasms and their trends. The data is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

• According to Aleksandra Ozygała et al., 2024, myeloproliferative neoplasms are predominantly diagnosed around 60 years of age. Pediatric incidence is approximately 0.82 per 100,000 annually, whereas adult prevalence is reported to be nearly 100 times higher.
• According to Blake Langlais et al., 2025, the overall gender distribution among patients is relatively balanced, with about 51% males. However, subtype variations exist, including essential thrombocythemia 33.6% male, polycythemia vera 66.0% male, and myelofibrosis 52.4% male prevalence.
• According to Jonathan Coy et al., 2025, prevalence differs across ethnic groups, with myeloproliferative neoplasms reported in 30.3% overall cases. Rates include 28.5% among Hispanic or Latino patients, 26.9% among White patients, and 35.5% among Black individuals.
• According to Zaid Zahid et al., 2025, as per global burden of disease data, approximately 222,511 deaths were recorded from 1990 to 2019 in the United States. Mortality trends showed early increases, stabilization phases, and significant declines after 2015.

Country-wise Myeloproliferative Neoplasms Epidemiology

The myeloproliferative neoplasms epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

Across the covered regions, epidemiological patterns of myeloproliferative neoplasms demonstrate notable variation yet consistent disease burden. According to Ruben Mesa et al., the prevalence in the United States is approximately 13,000 for myelofibrosis, 134,000 for essential thrombocythemia, and 148,000 for polycythemia vera. As per Nouf Abutheraa et al., 2023, myeloproliferative neoplasms affect about 8 per 100,000 individuals in the United Kingdom. According to Josep Carreras, the incidence of essential thrombocythemia in Spain is around 20 cases per million annually. Similar epidemiological patterns have been reported across Germany, France, Italy, and Japan, supporting the need for continued regional surveillance and research.

Myeloproliferative Neoplasms: Treatment Overview

Treatment of myeloproliferative neoplasms focuses on symptom control, prevention of complications, and reduction of disease progression risk. Therapeutic approaches include cytoreductive therapies such as hydroxyurea and interferon to control blood cell counts, along with targeted therapies like Janus kinase (JAK) inhibitors for patients with symptomatic disease or myelofibrosis. Low-dose aspirin is frequently used to reduce thrombotic risk in selected patients. Supportive care, including transfusions and management of anemia, is important in advanced stages. Hematopoietic stem cell transplantation remains the only potentially curative option, but it is typically reserved for high-risk or younger patients due to significant treatment-related risks.

Key Questions Answered

• What are the key findings of myeloproliferative neoplasms epidemiology in the 8 major markets?
• What will be the total number of patients with myeloproliferative neoplasms across the 8 major markets during the forecast period?
• What was the country-wise myeloproliferative neoplasms epidemiology scenario in the 8 major markets in the historical period?
• Which country will have the highest number of myeloproliferative neoplasms patients during the forecast period of 2026-2035?
• Which key factors would influence the shift in the patient population of myeloproliferative neoplasms during the forecast period of 2026-2035?
• What are the currently available treatments for myeloproliferative neoplasms?
• What are the disease risks, signs, symptoms, and unmet needs of myeloproliferative neoplasms?

Scope of the Myeloproliferative Neoplasms Epidemiology Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of myeloproliferative neoplasms based on several factors.
• Myeloproliferative Neoplasms Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The myeloproliferative neoplasms report helps to identify the patient population, and the unmet needs are highlighted along with an assessment of the disease's risk and burden.